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In the search for models for studying the pathogenesis of Down syndrome in 
man,  mouse  trisomy  16  has  been  identified  as  an  animal  model  for  human 
trisomy 21  (1,  2).  This identification  is based on comparative genetic mapping 
studies  demonstrating  that  three  genes  on  the  distal  part  of the  long arm  of 
human  chromosome  21  are  syntenic  in  the  mouse and  are  located on  mouse 
chromosome  16  (3-6).  The  existence of this  synteny in  both  man  and  mouse 
indicates  that  a  significant  chromosomal  segment  has been  evolutionari]y con- 
served (7), and  it is likely that  many other genes, yet to be identified,  are also 
conserved in  this region.  If this is the case, trisomy for mouse chromosome  16 
will  not only reproduce the genetic imbalance produced by human  trisomy 21 
of the three specifically mapped genes, but of many other homologous genes as 
well. 
Mice  with  trisomy  16  can  be  readily  bred,  and  initial  descriptions of these 
animals have already been published (8, 9). When trisomy 16 ~  2n aggregation 
chimeras prepared by joining trisomic and diploid (2n) preimplantation embryos 
and  then  transferring  them  into  foster  mothers,  were analyzed  at  the  end  of 
gestation, the proportion of trisomic cells in the thymus was significantly reduced 
(1).  In chimeras investigated between 2 and 5 mo after birth, marked reductions 
(to as low as  10%) were noted in the thymus, spleen, blood, bone marrow, and 
coat (pigment  cells).  These  findings  are  consonant  with  those of Herbst et al. 
(10) who observed that stern cells from nonchimeric fetal trisomy 16 livers were 
markedly impaired in their ability to restore hematopoiesis to lethally irradiated 
animals (radiation chimeras). 
In view of the fact that hematological and, in particular,  immunologic abnor- 
malities are known  to exist in  Down syndrome (11-13),  the finding of cellular 
defects in both types of chimeras was of considerable interest.  A  detailed study 
of the development and  function  of the  lymphoid and  hemopoietic systems in 
the mouse trisomy  16 fetus was therefore undertaken.  We report here that  the 
trisomic fetuses exhibit severe defects in many stem cell populations and devel- 
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oping lymphoid and erythroid tissues,  deficits out of proportion to the effects of 
the  trisomic  state  on  the  development  of other tissues  and organs.  Trisomy  16 
in  the  fetal  mouse  thus  results  in  a  state  of  genetically  caused,  combined 
inlmunodeficiency  and  anemia,  which  differs  from  all  of the  other  described 
hereditary  mouse disorders  of these types. 
Materials  and  Methods 
Generation  and Identification  of Trisomy  16 Mouse  Fetuses.  Trisomy  16 mouse fetuses 
were generated as previously described (I). Males doubly heterozygous for two metacentric 
chromosomes containing chromosome  16, Rb(16.17)32Lub/Rb(ll.16)2H,  were obtained 
from Professor Alfred Gropp and Dr. Heinz Winking, Medizinischen Hochschule L/ibeck, 
Liibeck, Federal Republic of Germany, and mated with C57BL/6 females. The pregnant 
females were killed by cervical dislocation at different stages of gestation and the fetuses 
removed.  The genetic status of each fetus,  which could be judged from the phenotype 
(massive edema in midgestation and short, thick neck, flat snout, and open eyelids in late 
gestation), was verified by karyotypic analysis of tail cells (fibroblasts) cultured for 5-7 d. 
Between 15 and 20% of the progeny of a C57BL/6 X Rb32Lub/Rb2H cross will be trisomic 
for chromosome 16, and the remainder will be diploid. Monosomy 16 embryos die at the 
time of implantation. 
Preparation  and Enumeration  of Cell Suspensions.  For the enumeration  of the cells in 
fetal  livers,  the  livers  were  minced  in  a  drop  of Dulbecco's modified  Eagle's medium 
(DME) a supplemented  with  2%  fetal  calf serum  (FCS), and a  single-cell suspension  was 
obtained  by repeated  passage of the  suspension  through a  25  gauge needle.  Red cells 
were lysed with ice-cold hypotonic (0.085%) saline, and the liver cells were then washed 
in DME with 2% FCS and suspended in 1 ml of the medium. Total cell counts and viability 
were ascertained on 1:5 dilutions of the suspension in 0.1% erythrocin B (Aldrich Chemical 
Co., Milwaukee,  WI) in phosphate-buffered saline (PBS).  For the quantitation  of spleen 
cells, the same procedure as for fetal liver was followed except that the medium was DME 
with  10%  FCS. For quantitation  of thymus cells, the same procedure was also followed, 
using DME with 2%  FCS. Thy-l-positive thymocytes were identified after staining with 
fluorescein  isothiocyanate  (FITC)-conjugated  anti-Thy-l.2  serum  (Becton,  Dickinson 
Monoclonal Center,  Inc., Mountain View, CA). 
Quantitation  of Stem  Cell Populations.  CFU-S (colony-forming units-spleen)  were as- 
sayed by the method of Till and McCulloch (14).  C57BL/6 mice were x-irradiated with 
800 rad. Within 4 h of irradiation, each animal received an injection through the tail vein 
of 0.2 ml of a suspension of day 16 fetal liver cells in PBS. The animals were killed 8-9 d 
after  injection,  the  spleens  removed and  fixed in  Bouin's solution,  and  the  number  of 
spleen colonies determined, 
CFU-C (colony-forming units-culture)  were assayed by a  modification of the method 
of Moore and Metcalf (15). Briefly, for each 35 mm plate, 5  x  105 to 1 x  10  6 fetal liver 
cells were suspended in  1 ml of 0.5%  Bacto-agar (Difco Laboratories, Inc., Detroit,  MI) 
in  RPMI  1640 (Gibco Laboratories,  Grand  Island,  NY),  to which was added 0.1  ml of 
giant cell  tumor (GCT)-conditioned  medium  (Gibco  Laboratories),  a  source of colony- 
stimulating activity. The plates were incubated for 6-7 d at 37°C in 5% CO~ in air, and 
scored for colony formation.  In some experiments,  the  GCT-conditioned medium  was 
omitted and the liver cells were plated over a 24-h-old feeder layer of STO cells that had 
been treated with  10 #g/ml mitomycin C at 37°C for 2 h (16). The identities of the cells 
in  the  colonies  were  verified by staining for peroxidase  (granulocytes) and  nonspecific 
esterase (monocytes). 
1  Abbreviations used in this paper:  A-MuLV, Abelson murine leukemia virus; BFU-E, burst-forming 
units-erythroid; CFU-B, colony-forming  units-B lymphocyte; CFU-C, colony-forming units-culture; 
CFU-E, colony-forming units-erythroid CFU-S, colony-forming units-spleen;  Con A, concanavalin 
A; DME, Dulbecco's modified  Eagle's medium; FCS, fetal calf serum;  FITC, fluorescein  isothiocya~ 
hate; GCT, giant cell tumor; IL-2, interleukin  2; PHA, phytohemagglutinin; PBS, phosphate-buffered 
saline; R1TC, tetramethylrhodamine isothiocyanate; SRBC, sheep red blood cells. FPSTEIN  ET AL.  697 
CFU-B (colony-forming units-B  lymphocyte) were  enumerated  in  fetal  livers  as  de- 
scribed by Paige (17). Briefly, 105 day-17 fetal liver cells were plated in 0.3% Bacto-agar 
over a normal, day-17 fetal liver-adherent  cell layer covered with Bacto-agar containing 
50 #g/ml lipopolysaccharide B. The cultures were incubated for 8 d at 37°C in 5% CO2 
in air, and a cell plaque assay performed as described by Paige and Skarvall (18). 
BFU-E (burst-forming  units-erythroid)  and  CFU-E  (colony-forming units-erythroid) 
were assayed in day-14 fetal liver as described by Rich and Kubanek (19). To quantitate 
CFU-E, sheep plasma erythropoietin (Step III; Connaught Laboratories, Inc., Swiftwater, 
PA) was added at concentrations of 0.08 or 0.25 U/ml and the cultures were incubated 
in a  37°C humidified incubator with 5% CO2 for 36-48 h. The plates were stained with 
benzidine hydrochloride (Sigma Chemical Co.) (20) and scored under an inverted micro- 
scope; CFU-E were identified as aggregates consisting of at least eight cells that stained 
blue after 5 min. 
To quantitate  BFU-E, sheep plasma erythropoietin was used at concentrations of 1 or 
2  U/ml, and the cultures were incubated in a  37°C humidified incubator with  5% CO2 
for 10 d. Using an inverted microscope, the plates were scored either unstained or after 
staining with benzidine. 
Detection of Pre-B and B Cells in Fetal Liver.  For the quantitation of pre-B and B cells, 
liver  cell  suspensions  were  prepared  as  described  above  and  stained  by  a  procedure 
provided by Dr. John  Kearney (University of Alabama,  Birmingham,  AL).  One to two 
million liver cells were pelleted and stained for surface-bound IgM with FITC-conjugated 
goat anti-mouse t* chain antibody (a gift from Dr. John Kearney) used at a concentration 
of 0.5 mg/ml and a fluorescein/protein ratio of 2.2:1. Cytocentrifuge slide preparations 
of the stained cells were made using a Cytospin II (Shandon Southern Instruments,  Inc. 
Sewickley, PA) and, after air drying, the slides were fixed and washed four tinaes  in PBS. 
At this stage, the slides can be kept refrigerated in PBS or used immediately for staining 
of cytoplasmic IgM. 
To detect cytoplasmic bound lgM, tetramethylrhodamine  isothiocyanate (RITC)-con- 
jugated goat anti-mouse ,, chain antibody (a gift from Dr. John Kearney) was used at a 
concentration of 0.2 mg/ml and a rhodamine/protein ratio of 1.0:1. After being washed 
in PBS, the slides were mounted with 75% glycerol (Mallinckrodt, Inc., St. Louis, MO) in 
PBS  and  covered  with  a  glass  coverslip;  fluorescence  was  determined  using  a  Zeiss 
Photomicroscope III. Surface-positive B  cells were small  and showed a  characteristic  B 
cell  pattern  of fine  spotty  staining.  Under  RITC  illumination,  pre-B  cells  showed  a 
characteristic  perinuclear  staining,  often  Golgi  associated,  but  were  surface  ~.  chain 
negative. 
Transformation with Abelson Murine Leukemia  Virus (A-MuLV).  Day-17 fetal liver cells 
were  transformed  with  A-MuLV in  semi-solid agarose as described  by  Rosenberg and 
Baltimore (21), using an A-MuLV stock prepared from 54/C12  cells (kindly provided by 
Dr. Naomi Rosenberg, Massachusetts Institute of Technology, Cambridge, MA). 
To  assay  for  transformation  with  A-MuLV  in  liquid  medium,  1  ml  cell  suspension 
containing 2 x  106 cells was mixed with  1 ml A-MuLV stock in a plastic tube. Polybrene 
was added at a concentration of 4/~g/ml, and the tubes were incubated in a humidified 
37 °C incubator in 5% C Oz for 2.5 h, with agitation every 15 min. After virus adsorption, 
the cell suspensions were diluted 1:20, 1:10, or 1:2 with RPMI 1640 containing 20% FCS, 
50  ~,M  2-mercaptoethanol,  and  2  jag/ml  polybrene,  and  0.1  ml  aliquots  of the  cell 
suspension  were  dispensed  into  wells  of a  96-well  microplate  (Micro  Test  III: Falcon 
Labware,  Oxnard,  CA).  The  cultures  were  refed  with  0.1  ml  complete  RPMI  1640 
medium on day 4, and visible colonies were scored on day 12 using an inverted microscope. 
Fetal Thymus Organ Culture and Thymocyte Stimulation.  Fetal thymuses taken from day- 
14 or day- 17 mouse fetuses were cultured in vitro by the method of Robinson and Owen 
(22).  For mitogen stimulation  experiments,  individual  lobes of thymuses were removed 
from culture and teased apart with fine-nosed forceps in 0.1 ml RPMI 1640 medium with 
15% FCS in a flat-bottomed, 96-well microtiter plate (Falcon Labware). An aliquot of the 
cell suspension  was diluted  with  0.1%  erythrosin in  PBS and counted. The thymus cell 
suspension was then adjusted  to a concentration of 6  x  105 viable cells/ml, and 0.05-ml 698  STEM  CELL  AND  THYMIC  ABNORMALITIES  IN  MOUSE  TRISOMY  16 
aliquots (3 x  104 cells) were dispensed into wells of round-bottomed, 96-well microtiter 
plates. Reagent grade phytohemagglutinin (PHA) (Wellcome Reagents Ltd., Beckenham, 
England) and concanavalin A type IV-S (Con A) (Sigma Chemical Co.) were each diluted 
in PBS to concentrations of 4.2 or 8.3 #g/ml, and 0.01 ml of either was added to the test 
wells. For control cells, an equivalent volume of PBS was added. After 48 h in culture in 
5% CO2 in air,  I #Ci of [3H]thymidine in 0.01  ml PBS was added to each well, and the 
plates were incubated an additional 18-24 h. The cultured cells were then harvested onto 
glass fiber filters wtih an automatic cell harvester (MASH; Otto Hiller Co., Madison, WI) 
as described by Goldblatt et al. (23). After drying, the filters were placed into scintillation 
fluid and counted. 
Assay for Interleukin 2 (IL-2) Production.  The IL-2 activity of the supernatant fluids 
from the Con A-stimulated fetal thymocytes was determined by the T  cell growth assay 
described by Gillis et al. (24),  using CTLL-A2 cells (a cloned, H-2Dd-specific,  cytotoxic, 
IL-2-dependent T  cell line) as the responding cell. The 1L-2 activities of the supernatant 
fluids are expressed relative to the activity of a standard rat IL-2 preparation. 
Enumeration of Germ Cells.  Day-12 fetuses were fixed in  10%  neutral buffered for- 
malin, infiltrated in glycol methacrylate (25), cut at 2 #m on a JB-4 microtome (DuPont 
Co., Sorvall Instruments Div., Newtown, CT) with glass knives, and every fifth section air 
dried to a slide. To identify germ cells, the sections were stained for alkaline phosphatase 
as described by Sheehan and Hrapchak (26),  using a 2 h incubation at 37°C. The nuclei 
were then stained with  0.1%  aqueous neutral  red,  the slides  air dried, and coverslips 
applied with Permount (Fisher Scientific Co., Pittsburgh, PA). 
Statistical Calculations.  Except as noted otherwise, all statistical  comparisons were done 
using the nonparametric Wilcoxon signed rank test. 
Results 
Deficiencies  of Cell  Populations  in  Trisomic  Organs.  Overall,  the  trisomy  16 
mouse fetuses were modestly retarded in development, with total fetal weights 
reduced ~25%  compared with diploid siblings over the last week (days  14-19) 
of gestation. For this reason, comparisons of the numbers of cells in trisomic and 
diploid fetal thymuses, spleens,  and  livers were carried out on a  weight rather 
than  length-of-gestation  basis.  Profound  deficiencies of cells  occurred in  both 
the thymus (Fig.  1) and spleen (Fig.  2), with the trisomic organs showing >80% 
decreases  in  total  cell  number  at  all  stages  of development.  By  contrast,  the 
number  of cells  in  the  livers  of trisomic  fetuses  were  decreased  only  ~50% 
throughout the period studied.  Circulating red cells were also decreased,  with 
the  mean  red  cell count of trisomic  day-17  fetuses  reduced  by  36%  (5.45  vs. 
8.56  X  10 6 cells/ml).  The mean hematocrit of trisomic day-18 fetuses was 52% 
lower  than  that  of diploid  controls:  14.3  _+  1.6%  (SEM)  and  30.0  +  1.2%, 
respectively. 
In addition to its small size, the trisomic thymus was abnormally located. Late 
in gestation, rather than anteriorly overlying the heart, it was high in the thorax 
near the great vessels and  trachea.  Furthermore, the trisomic thymocytes were 
somewhat  retarded  in  the  expression  of the  Thy-1  antigen.  On  day  17,  the 
proportions of Thy-l-positive cells in trisomic and diploid fetal thymuses were, 
respectively, 88.7  +  4.5%  and  91.4  +  2.1%.  However, on  day  18,  the  values 
were 79.3 +  6.8% and 95.3 +  0.9%, respectively, a difference significant at P  < 
0.005. 
Myeloid  Granulocytic,  and Erythroid Stem  Cell Deficiencies in  the Trisomic  Fetal 
Liver.  In addition to decreases in overall organ cell numbers, specific stem cell 
populations were also found to be markedly decreased in the trisomic liver. The EPSTEIN  ET AL.  699 
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FIGURE  i.  Number of cells per thymus in trisomic (Tsl6) and diploid (2n) fetuses, expressed 
as a function of fetal weight. Each point represents an individual fetus. The curve for fetuses 
is shown on top and is reproduced with a dashed line in the lower panel, which shows the data 
for  trisomic fetuses. The  curves  were  obtained by  fitting the data  to  the best exponential 
function by the method of least squares. 
myeloid stein cell population defined by the CFU-S assay was studied on day 16 
of fetal development using livers from sibling animals (Table  I).  In two inde- 
pendent experiments, the total numbers of CFU-S in the trisomic livers were 27 
and 33% of the numbers in the diploid controls. 
The granulocyte-macrophage stem cells identified by the CFU-C assay were 
also markedly diminished during days  14-18  of gestation (Table  II).  Using a 
GCT-derived colony-stimulating  activity, the numbers of colonies per liver were 
decreased in  trisomic livers by >90%  on days  14  and  16  of gestation and by 
-80%  on day  18.  When an  STO  cell  feeder layer was  used as  the source of 
colony-stimulating activity, total colony numbers were greater than with GCT- 
conditioned medium. Nevertheless, although the deficiency was less severe on 
day  16,  the same profound decrease in CFU-C in trisomic livers was noted on 
day 14. 
Two erythroid stem  cells,  the  more primitive BFU-E and the later CFU-E, 
were  assayed in  day-14  fetal  livers  (Table  II1).  Like the  stem  cells  described 
previously, the number of trisomic BFU-E was severely reduced. Relative to the 
number of cells used in the assay, reduction was 60-80%.  However, on a total 
liver basis,  the reduction was even greater, 80-90%. In contrast, the decrease in 
CFU-E was considerably less, with normal relative numbers and only an ~50% 
decrease in total number per liver, as would be expected from the reduced size 
of the trisomic liver. 700  STEM 'CELL  AND  THYMIC  ABNORMALITIES IN  MOUSE  TRISOMY  16 
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FIGURE 2.  Number of cells per spleen in trisomic (Ts16) and diploid (2n) fetuses, expressed 
as a function of fetal weight. See legend to Fig. 1 for further details. 
TABLE  I 
CFU-S in Day-16 Trisomy 16 Fetal Livers 
CFU-S 
Experiment 1  Experiment 2 
Tsl6  2n  Tsl6  2n 
Number of cells injected 
4.0 x  l0  b  15.6 
2.4 x  105  10.5 
0.8 x  105  2.8 
Mean per 106 cells  39.3 
Cells per liver x  l0  -6  (6.2) 
CFU-S per liver  243 
Tsl6 
2n 
11.6  9.8  15.6 
6.8  6.5  8.6 
3.2  1.8  4.2 
32.4  24.7  43.9 
(28.0)  (22.7)  (39.3) 
908  561  1723 
0.27  0.33 
l)ata represent the mean spleen colony count of three (occasionally two) animals receiving the same 
number of fetal liver cells. 
Pre-B and B Lymphocyte Deficiencies  in Trisomic Liver.  Two methods were used 
to assess the number of pre-B and B  lymphocytes in fetal liver (Table IV). The 
first,  based  on  immunofluorescent staining of pre-B  and  B  lymphocytes with 
antibodies against #  chains, revealed a  <20%  decrease in the relative number of 
these cells in day  17 and  18  trisomic livers. The  other,  using a  colony-forming 
assay for CFU-B, revealed a  statistically nonsignificant 15% decrease in colonies EPSTEIN  ET AL. 
TABLE  II 
CFU-C in Trisomy 16 Fetal Livers 
701 
Colonies per 106 fetal liver cells  Colonies per liver 
Day of  GCT growth factor  STO cell feeder layer  GCT growth factor 
gestation 
Tsl6  2n  Tsl6/2n  Tsl6  2n  Tsl6/2n  Ts/16  2n  Tsl6/2n 
STO cell ~ederlayer 
Tsl6  2n  Tsl6/2n 
14  2.0  52.0  0.04  18  143  0.13  16  829  0.02  140  2,239  0.06 
0  15.0  0  14  107  0.13  0  204  0  142  1,556  0.09 
4.4  28.4  0.15  44  588  0.07 
16  2.7  30.8  0.08 
3.8  31.5  0.12 
17  3.9  12.5  0.31 
18  6.3  12.6  0.50 
64  74  0.86  21  302  0.07  431  700  0.62 
31  74  0.42  55  707  0.08  357  1,611  0.22 
114  511  0.21 
Each point represents the mean of three (occasionally two) replicate  plates; the results  of individual experiments are placed  in separate  rows. 
The GCT growth factor and STO cell feeder layer experiments were carried out on the same cell preparations. 
TABLE  III 
Erythroid Stem Cells (BFU-E and CFU-E) in Day-14 Trisomy 16 Fetal Livers 
Cells per 
plate 
Erythropoi-  Colonies per plate 
etin concen-  Tsl6 
tration  Ts 16  2n  P* 
2n 
Colonies per liver x  10 -3 
Tsl6 
Tsl6  2n  P 
2n 
BFU-E 
4x  104 
7.5 x  l04 
CFU-E 
4×  104 
U/ml 
1 
2 
1.4  3.7  <0.05  0.38 
1.8  9.8  <0.005  0.18 
1.6  7.7  <0.005  0.20 
0.08  1,040  980  -- 
0.25  1,190  1,040  NS 
1,060  860  -- 
Combined  1,150  990  NS 
0.19  1.02  0.18 
0.11  1.09  0.10 
142  362  --  O.39 
166  328  NS  0.51 
234  403  --  0.58 
186  349  0.05  0.53 
For BFU-E, each value represents the mean of two or four replicate plates; for CFU-E, the mean 
of two to five assays from individual animals, each performed in duplicate. 
* Calculated by Wilcoxon rank sum test. NS, not significant. 
TABLE  IV 
Pre-B and B Lymphocytes in Trisomy 16 Fetal Livers 
Immunofluorescence  CFU-B 
Day of 
gestation  Genotype  Proportion (percent  of total cells)  Tsl.~6  Colonies per  T...2s  Colonies per  Tsl6 
B  Pre-B  B +  Pre-B  2n  10  s liver cells  2n  liver x  10  4  2n 
17  Tsl6  0.43 -+ 0.19  2.68 ±  1.10  3.12--.0.74"]  22.4±3.9  l  0.85  2.12±0.43"] 
2n  0.24 ±  0.10  3.53  -+ 0.69  3.77 ± 0.65  0.83  26.5  + 3.1  5.37 + 0.87  0.39 
18  Tsl6  2.46-  +  1.02  3.84_+0.90  6.50±0.42  l  0.93 
2n  2.15-+0.42  4.97-+0.43  7.01-+0.61 
The imnmnofluorescence  data are expressed  as mean -  SEM of 5-15 individual  animals and represent proportions of cells expressing  surface 
(B) and cytoplasmic only (pre-B) ,a chains; the Tsl 6]2n ratio is expressed  for the proportions of B + pre-B cells. The CFU-B data are expressed 
as mean --- SEM of 9 and 20 determinations for Tsl6 and 2n livers, respectively. 702  STEM  CELL  AND  THYMIC  ABNORMALITIES  IN  MOUSE  TRISOMY  16 
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FIGURE 3.  Transformation in agar of trisomic (Tsl6) and diploid (2n) fetal liver cells by A- 
MuLV. Each point represents the mean of three replicate plates from a single liver preparation. 
per 105 liver cells on day 17, but, when expressed on a total liver basis, the mean 
value in trisomic livers was decreased by 61% (P <  0.005). 
Insensitivity  of Fetal Liver Cells to Transformation  by A-MuLV.  Because of our 
interest  in  a  possibly  enhanced  sensitivity  of trisomy  16  pre-B  and  B  cells  to 
leukemogenic transformation (see Discussion), we exposed trisomic and control 
liver cells  from day-17  or day-18  fetuses  to  A-MuLV  in  vitro and  scored the 
appearance  of transformed  colonies.  When  the  assay  was  carried  out  in  agar 
culture,  there  was  a  profound  decrease  (94%,  P  <  0.005)  in  the  number  of 
colonies. The means for trisomic and diploid liver cells were 3.7 +  1.2 and 61.4 
___  9.0  colonies  per  10 6  cells,  respectively  (Fig.  3).  When  the  transformation 
occurred in  liquid culture, the respective means were 4.7  +  1.3 and  127 +  16 
colonies per 106 cells, a decrease of 96%. These decreases could not be attributed 
to equivalent decreases in the proportion of pre-B and B lymphocytes, for which 
results were presented in Table IV. 
Normal Rates of  Proliferation But Deficiency in Cell Numbers in Trisomic Thymuses 
Grown in Organ  Culture.  To ascertain whether the reduction in the number of 
lymphocytes in trisomic thymuses is the result of a decreased rate of lymphocyte 
proliferation,  a  decreased  number  of early thymocytes, or  both,  we  removed 
day-14 thymuses and cultured one lobe of each in vitro for 7 d. The other lobe 
was  analyzed  at  the  time  of initiation  of the  cultures.  Two  experiments  are 
illustrated in Fig. 4. During the week of culture, the increase in cell number was 
10-12-fold,  with the rates for trisomic and diploid thymuses being indistinguish- 
able.  As a  result, the 78% reduction in cell number in trisomic thymuses at the 
time of explant was matched by an 82% reduction after 7 d  in culture. Further- 
more, despite these large differences in cell numbers, the proportion of lymphoid 
cells in  the thymuses,  both before and after culture, and  of large  lymphocytes 
after culture,  was  not  significantly different between  the  trisomic and  diploid EPSTEIN  ET AL.  703 
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FIGURE  4.  Proliferation ofthymocytes in trisomic (Tsl6) and diploid (2n)  fetal thymic lobes 
cultured in vitro. For each pair of points connected with a  line, the day 0  count was obtained 
from one lobe of a  thymus and the day  7  count from the other lobe after 7  d  of culture in 
vitro. Data from two different experiments are shown. 
thymuses. Both sets of results suggest that abnormalities  in the proliferation of 
thymocytes are not the principal problem in the trisomic thymus. 
Delayed Functional Maturation  of Thymic Lymphocytes in Trisomic Thymuses Grown 
in Organ Culture.  To study the functional capacities of trisomic T  lymphocytes, 
as manifested by proliferative and IL-2 production responses to mitogens,  fetal 
thymuses were explanted at day 17 and cultured in vitro for up to 17 additional 
days. As expected, the initial  cell count was much higher  in the diploid than  in 
the trisomic thymuses, 1.54 (___0.41) ×  106 vs. 0.15 (+0.03) X 10 6 cells per thymic 
lobe (Fig.  5).  However,  while  the  number  of trisomic  cells  increased,  with  a 
somewhat wavelike pattern,  during the period of culture,  the diploid thymuses 
demonstrated an early precipitous drop in cell number before demonstrating  a 
level quite close (within  a  factor of two) to that  in  the trisomic thymuses. This 
drop in cell number was also reflected in the decrease in the viability of the cells 
in the diploid thymuses during the first week of organ culture, from a mean cell 
viability of 84% in the trisomic thymuses to 63% in the diploid organs (Fig. 5). 
When  the  proliferative  response  of  the  cultured  fetal  T  lymphocytes  to 
mitogenic stimulation  was assessed, it was found that PHA was a poor mitogen. 
All further experiments were therefore carried out with Con A, and the results 
of a  large  number  of determinations  are  shown  in  Fig.  6.  For  diploid  fetal 
lymphocytes, the maximal response occurred after 9-10 d in culture. In contrast, 
the trisomic cells, although showing an early peak in the stimulation index after 
10 d in culture, did not reach their maximal responsiveness until after  15-16 d. 
At that  time  the trisomic  lymphocytes showed a  response seven to eight times 
greater than that of the diploid cells. 
In  general  terms,  the  curves  for  IL-2  production  are  similar  to  those  for 
proliferation,  with  the  trisomic cells showing a  somewhat lower response  than 704  STEM  CELL  AND  THYMIC  ABNORMALITIES  1N  MOUSE  TRISOMY  16 
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FIGURE 5.  Mean  cell counts (top) and viabilities (bottom) of trisomic (Tsl6) and diploid (2n) 
thymocytes from day-17 fetal thymuses cultured  in vitro. Each point represents the mean _+ 
SEM of 12-4 ] thymic lobes for the diploid fetuses and 8-22 lobes for the trisomics. 
the diploid  cells for the  first  13  d  of culture  and  then a  much higher  response 
after 15-17 d (Fig. 6). However, when IL-2 production was plotted as a function 
of the mitogenic response to Con A, there was only a  weak correlation between 
the two: r =  0.50 for the trisomic and diploid data combined, and 0.42 and 0.55, 
respectively, for the diploid and trisomic data separately. 
Normal Numbers of Germ Cells in the Genital Ridges.  Because of the  frequent 
association  of germ  cell  deficiencies  or  sterility  with  hereditary  anemias,  we 
undertook to determine whether trisomy 16, with its multiple stem cell deficien- 
cies,  also  had  a  germ  cell  defect.  The  mean  total  embryo  germ  cell  counts 
obtained in this manner were 3,585  _+ 450  (n =  8) and 2,476  _+ 514 (n =  5) for 
diploid  and  trisomic embryos, respectively.  Although  the  overall mean  for the 
trisomic embryos was  31%  lower than  for the  normal ones,  the  difference was 
not statistically significant. 
Discussion 
Trisomy for chromosome 16 in the mouse had profound effects on all aspects 
of hematopoietic  stem  cell  differentiation  that  have been  studied.  There  were 
marked deficiencies of several stem cell and precursor populations,  ranging,  on 
an absolute (per fetus or liver) basis, from 40 to 60% in late erythroid stem cells EPSTEIN  FI"  AL.  705 
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FIGURE 6.  The proliferative responses and production of IL-2, after mitogenic stimulation 
with Con A, of lymphocytes obtained from day-17 fetal thymuses cultured in vitro for the 
time specified on the abscissa. After release from the cultured thymus, the lymphocytes were 
cultured with Con A for 72 h; the medium was changed and [SH]tbymidine added 48 h after 
initiation  of  the  culture.  The  results  are  expressed  as  mean  incorporation  +  SEM  of 
[~H]thymidine by  the  stimulated cells  (bottom);  mean  ±  SEM  stimulation index  (cpm  in 
stimulated cultures/cpm  in  unstimulated cultures) (middle);  and  IL-2 content of the 48  h 
culture medium relative to a rat IL-2 activity standard (top). 
(CFU-E) and pre-B lymphocytes and CFU-B to 70-90%  decreases in multipoten- 
tial  (CFU-S),  granulocyte-macrophage  (CFU-C),  and  early  erythroid  (BFU-E) 
stem  cells. These  decreases  were  coupled with  severe reductions,  on  the  order 
of  50  to  _80%,  in  the  number  of  differentiated  cells  derived  from  these 
precursors,  reductions  that  were  reflected  in  a  reduced  hematocrit  and  in 
decreased  sizes and  cellularity of the late fetal thymus,  spleen, and liver. These 706  STEM  CELL  AND  THYMIC  ABNORMALITIES  IN  MOUSE  TR1SOMY  16 
reductions and decreases are out of proportion  to the moderate retardation  in 
growth and development that characterizes the trisomic condition. 
Although  all  of the  hematopoietic  cell  lineages  appear  to  be  affected,  the 
abnormality  of the  thymus  is  particularly  striking  and  T  lymphocytes appear 
much more severely affected than  the B lymphocytes. Our results suggest that 
the principal problem in the growth of the thymus is not in the proliferation of 
the  thymocytes  per  se.  Rather,  there  appears  to  be  a  reduced  number  of 
thymocyte precursors  settling  in  the  primordial  thymus,  either  because  of a 
decrease in their number in the fetal liver or because of an inhospitable environ- 
ment in the early embryonic gland. 
Even though thymocyte proliferation occurs at a normal rate in the developing 
trisomic fetal thymus, the thymocytes present in trisomic animals late in gestation 
demonstrate  distinct  differences  in  functional  maturation.  The  most  striking 
feature is a delay in the maturation  of the fetal thymocytes in vitro to a state of 
responsiveness to the mitogenic effect on Con A. It is noteworthy, however, that 
the  magnitude  of the  peak  response  was quite  similar  in  trisomic  and  diploid 
thymocytes. The delay in achieving peak responsiveness was also reflected in IL- 
2 production, a marker of T  helper cell function (27), although, in this instance, 
the trisomic cells were actually more responsive than normal cells (Fig. 6). Thus, 
although  maturation  is  delayed  for  both  functions,  the  ultimate  degree  of 
responsiveness  is  not  reduced.  However,  the  time  lag  does  suggest  that  the 
maturational  delays we observed with the trisomic thymuses in vitro may in part 
be related  to retarded  development of ttle trisomic thymus and  thymocytes in 
vivo.  In  addition  to  the  reduced  overall  growth  and  development  of trisomic 
fetuses, the modest reductions in the proportion of Thy-l-positive cells on days 
17 and  18 may be construed as evidence for such in vivo maturational  delay. 
Perhaps the most remarkable observation concerning the trisomic fetal cells is 
the very low susceptibility (<5% of control) of cells from the trisomy 16 liver to 
transformation  by A-MuLV. This result was totally unexpected since it was felt, 
by analogy with  the  increased  susceptibility of humans  with  trisomy  21  to the 
development of leukemia  (28),  if anything,  the murine  trisomic cells might  be 
more susceptible to viral transformation.  Available evidence suggests that undif- 
ferentiated cells of the B lymphocyte lineage are the targets for transformation 
by A-MuLV (29). However, we were unable, in our assays for both B and pre-B 
lymphocytes, to show a decrease in these populations of a degree anywhere near 
that required to explain the transformation results. Three other possibilities may 
therefore be considered. One is that the target cell for A-MuLV is a type of very 
primitive B cell that does not make a major contribution  to the cell populations 
detected by the assays used here and whose almost complete absence would not 
be detected.  Another possibility is that  the target  cell which is greatly reduced 
in number in  the fetal liver is not really a  B cell; in this regard,  it is of interest 
that  erythroid  colonies  have  been  obtained  from  A-MuLV-infected  day  9-12 
fetal liver. Finally, it is conceivable that the target cell population is not reduced 
at  all  and  that  the  trisomic  state  alters  the  target  cells,  making  them  highly 
resistant to transformation.  Further study is required to distinguish among these 
possibilities. 
As was mentioned  in  the introduction,  Herbst et al.  (10) observed that  stem EPSTEIN  ET AL,  707 
cells from fetal trisomy 16 livers were unable to restore normal hematopoiesis to 
irradiated normal hosts.  They also found, as did we,  that CFU-C and CFU-S 
were reduced in numbers, the former by >_75% and the latter by 50%,  on a 
relative basis. Moreover, similar to our findings, the relative reduction in trisomy 
16 CFU-C was greatest at 14-16 d gestation, when it was >90%. These stem cell 
deficiencies, as well as the others defined in the present work, can explain the 
poor reconstitution and limited survival of the radiation chimeras. In addition, 
they explain the  poor  representation of the  mature derivatives of these  cells 
(lymphocytes and erythrocytes) in the trisomy  !6 ~  2n  aggregation chimeras 
that we prepared. Although stem cells from some of the other mouse trisomies 
may also be defective, serious hematopoietic abnormalities are not necessarily a 
feature of mouse trisomies in general (30).  It seems fair to conclude, therefore, 
that the hematopoietic abnormalities in trisomy 16, while not necessarily unique, 
are characteristic of this particular form of genetic imbalance. 
Although  the  genetic  defect  in  trisomy  16  is  the  extra  copy  of a  normal 
chromosome carrying normal genes, and not a mutation or set of mutations, our 
striking  findings in  trisomy  16  invite  comparison  with  the  other  genetically 
caused immunodeficiencies and anemias in the mouse. These comparisons are 
shown  in  Table  V  and  include  those  conditions that  appear  to  result  from 
abnormalities in cellular development; autoimmune disorders are omitted. The 
marked deficiencies in lymphoid and granulocytic cell precursors and the absence 
of germ cell deficiency in trisomy 16  distinguish it from the W/W  ~ and Sl/Sl d 
forms of heterditary anemia (31,  32).  In this regard, it most closely resembles 
the immunodefi~ziencies with combined T  and  B  lymphocyte defects (33-35). 
However, the anemia and erythroid stem cell abnormalities in trisomy 16 indicate 
that the defects go beyond the lymphoid system and presumably involve very 
early hematopoietic stem cells or components common to several different cell 
types. Therefore, although complete information is not available on all mouse 
immunodeficiencies, trisomy 16 does not appear to be identical to any of them 
and produces more extensive hematopoietic aberrations. However, of all of the 
genetic immunodeficiencies and anemias thus far examined, only nu/nu  xid/Y, 
a combination of two independent mutations affecting both T and B lymphocytes, 
demonstrates a decrease in Abelson virus transformation similar to that found 
in trisomy 16 (29). 
We come, finally, to a consideration of the relationship between our observa- 
tions  in  trisomy  16  mice  and  the  immunologic and  hematologic findings in 
humans with trisomy 21, since it was the genetic relationship between these two 
trisomies that was originally responsible for the interest in mouse trisomy  16. 
Although  there  is  considerable  disagreement  in  the  literature,  a  picture  of 
immunologic impairment associated with human trisomy 21  has emerged (for 
review see reference 13). T  lymphocytes have often been reported as decreased 
in number (36),  with decreased ratios of helper to suppressor cells  as defined 
with monoclonal antibodies (12). ~ The proliferative response of lymphocytes to 
Philip, R.,  A. C.  Berger,  N.  H.  McManus, N.  H.  Warner,  M.  A.  Peacock, and L.  B.  Epstein. 
Numerical alterations in  lymphoid  subpopulations and abnormalities of the  in  vitro cellular  and 
humoral responses to bacterial and viral antigens in Down syndrome (trisomy 21). Submitted for 
publication. T
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mitogens  such  as  PHA  and  Con  A  has  also  been  frequently  reported  to  be 
decreased (37, 38), as has in vitro response to several antigens (11).  2 Of particular 
relevance  to  the  observations  reported  here  are  the  reports  of anatomic  and 
functional abnormalities of the thymus, including marked lymphoid depletion in 
infants,  enlargement  and  cystic  changes  of Hassall's  corpuscles  (36),  and  de- 
creased levels of serum thymic factors (39). Burgio et ai. (12) have suggested that 
all  of the immunologic problems in trisomy 21  result from a  primary defect in 
the thymus that interferes with the ultimate maturation of thymocytes into fully 
competent T  lymphocytes. Although anemia is not characteristic of trisomy 21, 
abnormal activities of  several erythrocyte enzymes suggestive of some impairment 
of erythropoiesis  have  been  noted  (40).  Similarly,  while  leukopenia  is  not  a 
feature  of  Down  syndrome,  disturbances  of granulocyte  kinetics  have  been 
reported (41) and a reduced number of circulating stem cells (CFU-C) has been 
described (42). 
It thus appears that, while the hematopoietic abnormalities in the two trisomic 
conditions are not identical,  those in  the mouse being much more severe than 
those  in  man,  interesting  parallels  can  be  drawn,  particularly  regarding  the 
thymus. The  evidence for thymic deficiency in  Down syndrome, coupled with 
the finding of dramatic  thymic hypoplasia in the trisomy mouse fetus, suggests 
that  the  same  or  a  similar  mechanism  might  be  operating  to  produce  the  T 
lymphocyte abnormalities in both species. If this should turn out to be the case, 
it  might  be expected  that  finer  genetic dissection  of the  trisomic  state  in  the 
mouse would  reveal  a  relationship  between  the  hematopoietic  defect and  the 
specific unbalanced gene or genes that causes it. However, even if the defects in 
the trisomy  16 mouse should prove dissimilar to those in  humans  with trisomy 
21, the trisomic mouse will still be worthy of consideration on its own merits and 
will provide valuable information  about the genetic control  of development of 
the  hematopoietic  system.  As with  the  other genetic abnormalities  of hemato- 
poiesis, the precise mechanisms  giving rise to the defects in trisomy  16 remain 
to be elucidated.  Although  many mechanisms  might be suggested, the relation- 
ships  between  the  presence  of an  extra  chromosome  and  the  developmental 
abnormalities are still  unknown (13). 
Summary 
Mouse fetuses with trisomy  16 have severe abnormalities  of several hemato- 
poietic stem cell and precursor populations. The thymus is extremely hypoplastic, 
with a  _>80%  reduction  in  the  number of thymocytes. This  cellular deficiency 
appears to be the result of a  deficiency in the number of precursor cells in the 
early thymus, since the rate of proliferation  of thymocytes in explanted day-14 
thymuses was normal.  However, the  functional  maturation  of thymocytes was 
delayed in vitro in day-17 organ explants, although the maximal response to the 
mitogenic and interleukin  2-stimulating effects of concanavalin A are quantita- 
tively normal. B cells and pre-B cells in the fetal liver were moderately decreased, 
but the ability of fetal liver cells to be transformed by Abelson murine leukemia 
virus  was nearly  totally lost.  There  were also significant  relative  and  absolute 
decreases in  the number of spleen, culture, and erythroid colony-forming units 
(CFU-S, CFU-C,  CFU-E) and  of erythroid  burst-forming  units  (BFU-E) in  the 710  STEM CELL  AND  THYMIC  ABNORMALITIES  IN  MOUSE TRISOMY  16 
trisomic liver, and the trisomic animals were anemic with small spleens and livers. 
However, unlike other genetically caused anemias, there was no reduction in the 
number of germ cells. The hematopoietic abnormalities in the trisomy 16 mouse, 
involving  the  lymphoid,  myeloid,  and  erythroid  cell  lineages,  are  much  more 
generalized  than  the  abnormalities  in  any  of the  other  described  genetically 
caused immunodeficiencies or anemias in the mouse. They are also more severe 
than those in human trisomy 21  (Down syndrome), for which mouse trisomy 16 
is a genetic model, but there does exist an interesting parallel between the thymic 
abnormalities in the two species. 
We thank  Mrs.  Teodosia Zamora for help in  breeding the trisomic mice,  Ms.  Linda J. 
Prentice for preparing the sections used to enumerate germ cells,  Dr. John Kearney and 
Dr. Naomi Rosenberg for reagents or cells, and Dr. Chris Paige for helpful advice. 
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